Bio Essence

Bio Essence Equity Ratio

The Equity Ratio of Bio Essence (BIOE) as of Oct 16, 2026 is -490.66 %. In the previous year, Equity Ratio was -1,056.53 % — a change of -53.56% (higher).

Equity Ratio

-490.66 %

YoY

-53.56%

Last updated:

Equity Ratio of Bio Essence is 2025 -490.66 % . Equity Ratio of Bio Essence was 2024 -1,056.53 % . It decreases by -53.56% higher compared to the previous year.

The Bio Essence Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
16.57 USD
Jan 1, 2019
-47.30 USD
Jan 1, 2020
-96.52 USD
Jan 1, 2021
-142.93 USD
Jan 1, 2022
-209.24 USD
Jan 1, 2023
-62.38 USD
Jan 1, 2024
-1,056.53 USD
Jan 1, 2025
-490.66 USD
The Bio Essence Equity Ratio history
YEAREquity RatioYoY
-490.66 %-53.56%
-1,056.53 %+1,593.82%
-62.38 %-70.19%
-209.24 %+46.39%
-142.93 %+48.09%
-96.52 %+104.07%
-47.30 %-385.36%
16.57 %-79.55%
81.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Essence Stock analysis

What does Bio Essence do? Bio Essence Corp, trading under the ticker BIOE with ISIN US09090C1053, is a U.S.-based company headquartered in Irvine, California. The company made its initial public offering on March 30, 2022. Bio Essence Corp operates through three subsidiaries: Bio Essence Pharmaceutical, Inc. (BEP), Bio Essence Herbal Essentials Inc. (BEH), and McBE Pharma, Inc. (McBE). BEP functions as an original equipment manufacturer (OEM) for health supplements. BEH serves the practitioners' market with herbal products available in granules, capsules, pills, and tablets, and offers special formulation services to healthcare practitioners. McBE focuses on the development, manufacturing, and sales of prescription drugs. The company provides nutritional supplements, including herbal, diet, and vitamin products, and facilitates direct connections between customers and integrative healthcare practitioners such as dietitians and nutraceutical practitioners. Bio Essence Corp does not specify its sector or industry in the provided information. The company’s business model emphasizes integrated health supplements and research-intensive products, though the nature of its research activities is not detailed. It operates without a publicly disclosed founding year, and no acquisitions or specific product names beyond the subsidiaries are mentioned. The company's operations are centered around its subsidiaries' distinct roles in the health supplement and pharmaceutical markets. Bio Essence is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Essence stock

Equity Ratio of Bio Essence is -490.66 % in 2025.

Equity Ratio of Bio Essence changed from -1,056.53 % to -490.66 %, representing a -53.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Bio Essence since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Bio Essence with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio Essence

All Key Metrics — Bio Essence